Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Michinori Matsumoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5860-1103; OpenAlex author ID A5049959626. Sources: OpenAlex.

Their work

Papers
20
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 4 papers · 2024: 4 papers · 2025: 6 papers · 2026: 4 papers

Papers 20

  1. Number of Liver Metastases Stratifies Prognosis in Synchronous Metastatic Pancreatic Cancer. Co-author DOI 10.1002/wjs.70666↗
  2. Prognostic stratification of unresectable locally advanced pancreatic cancer using a combination of inflammatory and nutritional indices: a retrospective cohor… Co-author DOI 10.1007/s00595-026-03344-7↗
  3. Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a multicenter study. Co-author DOI 10.1007/s00595-026-03416-8↗
  4. Sialic Acid-Fibronectin-negative and CD-44-positive Pancreatic Cancer Has a Poor Prognosis Due To Epithelial-Mesenchymal Transition. Co-author DOI 10.21873/anticanres.17965↗
  5. The minimum apparent diffusion coefficient value on preoperative magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biolog… Co-author DOI 10.1007/s00595-025-03050-w↗
  6. The preoperative cachexia index predicts outcomes after pancreatic resection for resectable pancreatic cancer. Co-author DOI 10.1007/s00595-025-03088-w↗
  7. Signal heterogeneity in apparent diffusion coefficient map of magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biologica… Co-author DOI 10.1016/j.suronc.2025.102270↗
  8. Impact of Preoperative Osteosarcopenia and Postoperative Administration of Pancrelipase on the Prognosis of Borderline Resectable and Unresectable Locally Adva… Co-author DOI 10.1177/00031348241272420↗
  9. Prognostic Impact of a Decrease in Serum Carbohydrate Antigen 19-9 Levels After Preoperative Therapy for 4 Months or More for Borderline Resectable Pancreatic … Co-author DOI 10.1177/00031348241278016↗
  10. Changes in Skeletal Muscle Volume During Preoperative Chemotherapy Affect the Outcome of Pancreatic Cancer. Co-author DOI 10.1177/00031348241278021↗
  11. Prognostic impact of osteosarcopenia in patients undergoing pancreatic resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-024-03315-x↗
  12. Prognostic significance of occult vertebral fracture in patients undergoing pancreatic resection for pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.01.003↗
  13. Effect of Risk Factor Score on Early Recurrence After Pancreatectomy for Invasive Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.16968↗
  14. Effect of Chemoradiotherapy on Locoregional Recurrence After Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17229↗
  15. Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer. Co-author DOI 10.1007/s00520-023-08206-3↗
  16. Superior mesenteric vein/portal vein contact in preoperative imaging indicates biological malignancy in anatomically resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2023.101998↗
  17. The Impact of Fibrinogen to Prognostic Nutritional Index Rate on Prognosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/00031348231204912↗
  18. Preoperative Therapy for Unresectable Locally Advanced Pancreatic Cancer for ≥6 Months Improves Prognosis After Pancreatectomy. Co-author DOI 10.21873/anticanres.16599↗
  19. Impact of osteopenia on surgical and oncological outcomes in patients with pancreatic cancer. Co-author DOI 10.1007/s10147-021-01986-w↗
  20. Incidental abdominal lymph node metastases from a known breast cancer in resected specimen of invasive pancreatic ductal adenocarcinoma: report of a case. Co-author DOI 10.1007/s13691-019-00382-6↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toru Ikegami · 19 shared papers, 2021–2026 · strength 4.19
  2. Koichiro Haruki · 18 shared papers, 2019–2026 · strength 3.82
  3. Kenei Furukawa · 17 shared papers, 2021–2026 · strength 3.67
  4. Yoshihiro Shirai · 17 shared papers, 2021–2026 · strength 3.63
  5. Masashi Tsunematsu · 16 shared papers, 2023–2026 · strength 3.53
  6. Shinji Onda · 15 shared papers, 2023–2026 · strength 3.23
  7. Takeshi Gocho · 9 shared papers, 2023–2026 · strength 2.10
  8. Ryoga Hamura · 9 shared papers, 2023–2026 · strength 1.91
  9. Norimitsu Okui · 7 shared papers, 2023–2026 · strength 1.58
  10. Mitsuru Yanagaki · 7 shared papers, 2023–2026 · strength 1.56
  11. Tadashi Uwagawa · 6 shared papers, 2023–2026 · strength 1.23
  12. Tadashi Uwagawa · 5 shared papers, 2024–2025 · strength 1.19
  13. Kyohei Abe · 6 shared papers, 2021–2025 · strength 1.12
  14. Yoshiaki Tanji · 5 shared papers, 2023–2026 · strength 1.01
  15. Tomohiko Taniai · 5 shared papers, 2019–2026 · strength 0.97
  16. Taro Sakamoto · 4 shared papers, 2019–2026 · strength 0.75
  17. Shunta Ishizaki · 3 shared papers, 2023–2025 · strength 0.63
  18. Yosuke Igarashi · 3 shared papers, 2023–2025 · strength 0.60
  19. Yuta Yamada · 1 shared paper, 2024 · strength 0.21
  20. Hironori Shiozaki · 1 shared paper, 2024 · strength 0.19
  21. Shuichi Fujioka · 1 shared paper, 2023 · strength 0.16
  22. Hiroaki Shiba · 1 shared paper, 2019 · strength 0.11
  23. Katsuhiko K. Yanaga · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.